| __timestamp | Bio-Techne Corporation | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 30945000 | 1513000 |
| Thursday, January 1, 2015 | 40853000 | 12573000 |
| Friday, January 1, 2016 | 45187000 | 42238000 |
| Sunday, January 1, 2017 | 53514000 | 69800000 |
| Monday, January 1, 2018 | 55329000 | 113773000 |
| Tuesday, January 1, 2019 | 62413000 | 179362000 |
| Wednesday, January 1, 2020 | 65192000 | 266946000 |
| Friday, January 1, 2021 | 70603000 | 438633000 |
| Saturday, January 1, 2022 | 87140000 | 461645000 |
| Sunday, January 1, 2023 | 92493000 | 387332000 |
| Monday, January 1, 2024 | 96664000 | 320653000 |
Data in motion
In the rapidly evolving biotech industry, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Bio-Techne Corporation and CRISPR Therapeutics AG have demonstrated contrasting R&D investment strategies. Bio-Techne's R&D expenses have steadily increased by approximately 212% from 2014 to 2023, reflecting a consistent commitment to innovation. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, has shown a more volatile investment pattern, with a staggering 25,500% increase from 2014 to 2022, before a slight dip in 2023. This fluctuation highlights the dynamic nature of the gene-editing field. Notably, data for 2024 is missing for CRISPR, indicating potential strategic shifts. As these companies continue to shape the future of biotechnology, their R&D investments offer valuable insights into their long-term visions and market positioning.
R&D Spending Showdown: AbbVie Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Insights: How Biogen Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Bio-Techne Corporation
Research and Development Investment: Incyte Corporation vs CRISPR Therapeutics AG
Bio-Techne Corporation vs CRISPR Therapeutics AG: SG&A Expense Trends
Analyzing R&D Budgets: Bio-Techne Corporation vs Geron Corporation
R&D Insights: How Lantheus Holdings, Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Arrowhead Pharmaceuticals, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Research and Development Investment: CRISPR Therapeutics AG vs Viridian Therapeutics, Inc.